In addition, the findings in this study also illustrated the possibility for CXCR4 to be a potential therapeutic target for treating prostate cancer, and inhibiting exosomal CXCR4 secretion may be a novel therapeutic against tumor development in the initial stage of prostate cancer. This evidence concerns the gene CXCR4 and prostate cancer.